Somerset-based Catalent announced it expanded its integrated development, manufacturing and supply solution, OneBio, across a range of biologic modalities, including antibody and recombinant proteins, cell and gene therapies and mRNA.
The launch of the expanded offering will coincide with Catalent exhibiting at the BIO International Convention — booth 785 — which takes place this week at the Boston Convention & Exhibition Center.
Originally launched in 2019 for early-phase protein therapy development, the OneBio suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.
Under the newly expanded OneBio offering, customers will continue to benefit from an integrated contract and proposal, harmonized project management, a global development and manufacturing network, and diverse expertise, now across biologic modalities and service offerings.
And for early-stage customers that need to develop and/or optimize their process towards good manufacturing practices, Catalent’s OneBio offering will include multimodality, turnkey platforms aimed to provide speed to clinical trial supply under the UpTempo brand.
“Since its launch, we have been able to demonstrate how beneficial the OneBio integrated biologics development solution can be to sponsors, saving them time on managing multiple partners, and handoffs between companies,” Karen Flynn, Catalent’s interim president, division head for biomodalities (cell, gene and protein therapies), said. “By expanding these services across multiple biologic therapies, Catalent is offering customers the opportunity to leverage its end-to-end capabilities in these areas and accelerate their programs to the clinic and beyond, mitigating potential risks and delays by providing planning efficiencies, an integrated contract, streamlined project management support, and harmonized quality systems.”
